Companies / Oncolytics Biotech Inc / Activity
Activity — Oncolytics Biotech Inc
28 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jan 16, 2026 | Seizinger Bernd R. Director | Buy | Common Shares | $103.8K | +100K +27.25% | 466,991 0.37% of shares | medium |
| Feb 11, 2026 | Seizinger Bernd R. Director | Buy | Common Shares | $49.6K | +60K +12.85% | 526,991 0.41% of shares | low |
| Feb 12, 2026 | Seizinger Bernd R. Director | Buy | Common Shares | $33.9K | +40K +7.59% | 566,991 0.44% of shares | low |
| Feb 12, 2026 | Andrews Patricia S Director | Buy | Common Shares | $30.3K | +35K +82.85% | 78,128 0.06% of shares | low |
| Feb 11, 2026 | Aromando Andrew Executive | Buy | Common Shares | $25.4K | +30K +116.08% | 55,100 0.04% of shares | low |
| Feb 12, 2026 | Pisano Wayne Director | Buy | Common Shares | $25.3K | +30K +6.49% | 492,414 0.39% of shares | low |
| Feb 12, 2026 | Kelly Jared CEO | Buy | Common Shares | $24.8K | +30K +37.11% | 109,000 0.09% of shares | low |
| Feb 12, 2026 | Brown Deborah Margaret Director | Buy | Common Shares | $21.2K | +25K +29.46% | 109,851 0.09% of shares | low |
| Mar 11, 2026 | Parsons James T. Director | Buy | Common Shares | $10.3K | +10K +31.40% | 41,849 0.03% of shares | low |
| Feb 12, 2026 | Look Kirk Executive | Buy | Common Shares | $10.1K | +12K +4.36% | 287,515 0.23% of shares | low |
| Feb 12, 2026 | Heineman Thomas Charles Executive | Buy | Common Shares | $10.0K | +12K +4.48% | 282,818 0.22% of shares | low |
| Feb 12, 2026 | Hagerman Allison Executive | Buy | Common Shares | $8.3K | +10K +9.52% | 115,059 0.09% of shares | low |
| Mar 12, 2026 | Kelly Jared CEO | Buy | Common Shares | $4.8K | +5K +4.63% | 114,050 0.09% of shares | low |
| Feb 11, 2026 | Kelly Jared CEO | Buy | Common Shares | $4.7K | +6K +7.58% | 79,500 0.06% of shares | low |
| Jun 1, 2026 | McAdory John Bearden Executive | Grant | Stock Option | — | +145K | 145,000 0.11% of shares | low |
| Jun 1, 2026 | Glover Stephen C. Director | Grant | Stock Option | — | +96K | 96,000 0.08% of shares | low |
| Jun 1, 2026 | Brown Deborah Margaret Director | Grant | Stock Option | — | +30K | 30,000 0.02% of shares | low |
| Jun 1, 2026 | Rigby Jonathan Director | Grant | Stock Option | — | +30K | 30,000 0.02% of shares | low |
| Jun 1, 2026 | Pisano Wayne Director | Grant | Stock Option | — | +30K | 30,000 0.02% of shares | low |
| Jun 1, 2026 | Holtham Angela Director | Grant | Stock Option | — | +30K | 30,000 0.02% of shares | low |
| Jun 1, 2026 | Look Kirk Executive | Grant | Stock Option | — | +260K | 260,000 0.20% of shares | low |
| Jun 1, 2026 | Parsons James T. Director | Grant | Stock Option | — | +30K | 30,000 0.02% of shares | low |
| Jun 1, 2026 | Aromando Andrew Executive | Grant | Stock Option | — | +260K | 260,000 0.20% of shares | low |
| Jun 1, 2026 | Kelly Jared CEO | Grant | Stock Option | — | +755K | 755,000 0.59% of shares | low |
| Jun 1, 2026 | Andrews Patricia S Director | Grant | Stock Option | — | +30K | 30,000 0.02% of shares | low |
| Jun 1, 2026 | Seizinger Bernd R. Director | Grant | Stock Option | — | +30K | 30,000 0.02% of shares | low |
| Jun 1, 2026 | Hagerman Allison Executive | Grant | Stock Option | — | +260K | 260,000 0.20% of shares | low |
| Jun 1, 2026 | Heineman Thomas Charles Executive | Grant | Stock Option | — | +260K | 260,000 0.20% of shares | low |